{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-119506","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.717615+00:00","generated_at":"2026-05-21T09:33:50.882083+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcellx reports 97% ORR and 68% CR/sCR in Phase 2 anito-cel study for RRMM","bullets":["Phase 2 iMMagine-1 (117 patients) showed 97% ORR and 68% CR/sCR at median 12.6 months follow-up.","No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) or immune-mediated enterocolitis.","12-month PFS rate 78.8%, OS rate 95.2%; median PFS and OS not reached.","Data to be presented at EHA2025 on June 14; commercial launch with Kite planned for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-119506","json":"https://secwatch.observer/filing/0001193125-25-119506.json","markdown":"https://secwatch.observer/filing/0001193125-25-119506.md","text":"https://secwatch.observer/filing/0001193125-25-119506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525119506/0001193125-25-119506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312525119506/d941498d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:33:50.882083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}